VIVEbiotech, a company specialized in the production of lentiviral vectors for their use in gene therapy, has received notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office.
VIVEbiotech, a company specialized in the production of lentiviral vectors for their use in gene therapy, has received notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office.
The World Advanced Therapies and Regenerative Congress took place at the Business Design Center in London from May 15 to 17.
VIVEbiotech has participated in two international conferences this past April.
Fourteen Colombian businessmen belonging to companies strongly implanted in Colombia visited VIVEbiotech on March 26.
VIVEbiotech participated in the FP-PARKE Forum that took place last Tuesday, March 12, at the Gipuzkoa Science and Technology Park.
The Lehendakari Iñigo Urkullu, President of the Basque Government, received the Board of Directors of VIVEbiotech yesterday in Lehendakaritza.
Mikeletegi Pasealekua 81, San Sebastián 20009, Gipuzkoa (SPAIN)
dummy +34 943 308 568
dummy info@vivebiotech.com